New brain-penetrant agonist shows promise in protecting dopamine neurons for Parkinson’s disease treatment

FHS
July 20, 2023
11:59 am

Researchers reported on Nurr1 as a promising therapeutic target for managing Parkinson’s disease (PD).

DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS – Biotech Investments

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE

August 20, 2024

Novo Nordisk stops trial of Ozempic in kidneys as interim analysis shows success – Pharmaceutical Technology

According to GlobalData, Novo Nordisk’s Wegovy (semaglutide) (indicated for obesity) and Ozempic are forecast to reach sales of $8.1bn and $2.1bn by 2031, respectively. Credit:

October 17, 2023

Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

Are generalist investors good or bad for biotech? How did Elaine and Adam’s trip to New York go? And how long has George Church owned

September 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.